Publication | Closed Access

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Diabetes ManagementInsulin DegludecDiabetesInsulin ManagementType 2Ultra-long-acting Basal InsulinDiabetes MellitusInsulin DeliveryMedicineInsulin Signaling